Skip to content

Lunai Bioworks Inc.: 10-Q filed 2026-05-15

What Lunai Bioworks Inc. reported in its quarterly report filed 2026-05-15 (fiscal Q3 2026): 40 published measures, 119 facts as tagged in accession 0001731122-26-000749.

This filing

Form
10-Q (quarterly report)
Filed
2026-05-15
Fiscal period
fiscal Q3 2026
Accession
0001731122-26-000749 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lunai Bioworks Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-03-319,860,540USD
At 2025-06-308,230,840USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-03-3119,413,968USD
At 2025-06-3029,580,681USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-03-31-9,553,428USD
At 2025-12-31-13,548,788USD
At 2025-09-30-13,040,774USD
At 2025-06-30-21,349,841USD
At 2025-03-3188,386,827USD
At 2024-12-3182,059,316USD
At 2024-09-3098,086,997USD
At 2024-06-30131,977,144USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-03-313,155,272USD
At 2025-06-3092,700USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-2,571,394USD90
2025-07-01 to 2026-03-31-1,551,778USD274
2025-10-01 to 2025-12-31-1,799,404USD92
2025-07-01 to 2025-09-302,819,021USD92
2025-01-01 to 2025-03-31189,176USD90
2024-07-01 to 2025-03-31-51,275,253USD274
2024-10-01 to 2024-12-31-7,252,394USD92
2024-07-01 to 2024-09-30-44,212,036USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-07-01 to 2026-03-31-3,447,179USD274
2024-07-01 to 2025-03-31-6,063,511USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-07-01 to 2026-03-311,238USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-01-01 to 2026-03-3120,942USD90
2025-07-01 to 2026-03-3120,942USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-07-01 to 2026-03-315,996,869USD274
2024-07-01 to 2025-03-318,204,415USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-07-01 to 2026-03-31543,462USD274
2024-07-01 to 2025-03-31-1,464,389USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-03-31-512,014,347USD
At 2025-06-30-510,462,570USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-01-01 to 2026-03-3124,994,200shares90
2025-07-01 to 2026-03-3123,742,675shares274
2025-01-01 to 2025-03-3116,233,457shares90
2024-07-01 to 2025-03-3116,137,745shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-01-01 to 2026-03-3124,994,200shares90
2025-07-01 to 2026-03-3123,742,675shares274
2025-01-01 to 2025-03-3116,393,047shares90
2024-07-01 to 2025-03-3116,137,745shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.1USD/shares90
2025-07-01 to 2026-03-31-0.07USD/shares274
2025-01-01 to 2025-03-310USD/shares90
2024-07-01 to 2025-03-31-3.18USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.1USD/shares90
2025-07-01 to 2026-03-31-0.07USD/shares274
2025-01-01 to 2025-03-310USD/shares90
2024-07-01 to 2025-03-31-3.18USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-03-3112,956USD
At 2025-06-30367,843USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-03-31168,993USD90
2025-07-01 to 2026-03-31479,124USD274
2025-10-01 to 2025-12-31128,819USD92
2025-07-01 to 2025-09-30181,312USD92
2025-01-01 to 2025-03-311,499,199USD90
2024-07-01 to 2025-03-312,415,478USD274
2024-10-01 to 2024-12-31558,631USD92
2024-07-01 to 2024-09-30357,648USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-1,477,260USD90
2025-07-01 to 2026-03-31-6,559,034USD274
2025-01-01 to 2025-03-31-4,162,492USD90
2024-07-01 to 2025-03-31-62,047,361USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-03-313,732,650USD
At 2025-06-301,046,632USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-03-3119,282,652USD
At 2025-06-3029,156,134USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-05167,259USD
At 2025-07-2517,050USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2026-03-315,963,000USD
At 2025-06-305,963,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2026-03-31119,115USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,448,202USD90
2025-07-01 to 2026-03-316,579,977USD274
2025-01-01 to 2025-03-314,162,492USD90
2024-07-01 to 2025-03-3162,047,361USD274

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-01-01 to 2026-03-3120,942USD90
2025-07-01 to 2026-03-3120,942USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-01-01 to 2026-03-3115,946USD90
2025-07-01 to 2026-03-3186,226USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-03-3135,772,800shares
At 2025-06-3017,739,291shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-03-313,155,272USD
At 2025-06-3092,700USD
At 2025-03-31923,002USD
At 2024-06-30220,467USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-03-31502,613,040USD
At 2025-06-30478,296,113USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-03-31-155,698USD
At 2025-06-3010,814,842USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-06-30687,371USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-03-316,114,934USD
At 2025-06-306,816,365USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-03-314,912,750USD
At 2025-06-305,843,069USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-2,588,069USD90
2025-07-01 to 2026-03-31-12,522,318USD274
2025-01-01 to 2025-03-314,812,390USD90
2024-07-01 to 2025-03-31-50,328,796USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,421,255USD90
2025-07-01 to 2026-03-315,597,980USD274
2025-01-01 to 2025-03-314,224,590USD90
2024-07-01 to 2025-03-3113,878,963USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2026-01-01 to 2026-03-3111,001USD90
2025-07-01 to 2026-03-3163,855USD274
2025-01-01 to 2025-03-3131,975USD90
2024-07-01 to 2025-03-3190,727USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-01-01 to 2026-03-31108,052USD90
2025-07-01 to 2026-03-31351,960USD274
2025-01-01 to 2025-03-31188,685USD90
2024-07-01 to 2025-03-31537,656USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-1,144,134USD90
2025-07-01 to 2026-03-315,007,257USD274
2025-01-01 to 2025-03-314,351,688USD90
2024-07-01 to 2025-03-3110,772,108USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-07-01 to 2026-03-31137,300USD274
2024-07-01 to 2025-03-3115,995USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-07-01 to 2026-03-311,417,035USD274
2024-07-01 to 2025-03-312,277,375USD274

Inspect the source

Entity
Lunai Bioworks Inc. / CIK 0001527728
Captured
2026-09-19T11:18:43.497Z
SEC response SHA-256
ac98dc0ce9d3f6a81ccca9ca1f946e5772f94eabe3529dac2d726fef17abed57

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001527728.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))